US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

3.70

+0.08002.21%

Volume:209.67K

Turnover:772.62K

Market Cap:307.82M

PE:-2.86

High:3.75

Open:3.62

Low:3.61

Close:3.62

52wk High:5.81

52wk Low:1.22

Shares:83.20M

Float Shares:65.21M

Volume Ratio:1.06

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2925

EPS(LYR):-0.8000

ROE:-4796.52%

ROA:-48.06%

PB:-23.70

PE(LYR):-4.62

Loading ...

Overview Company News Filings

Opus Genetics (IRD) Q1 Loss Of US$65.5 Million Intensifies Bearish Community Narratives

Simply Wall St.

Opus Genetics Is Maintained at Market Outperform by Citizens

Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary

Opus Genetics to present at RBC Capital Markets Global Healthcare Conference

Opus Genetics price target lowered to $11 from $12 at Citizens

Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH) and Opus Genetics (IRD)

Opus Genetics reports Q1 EPS (75c), consensus (14c)

Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate

Benzinga Earnings

Opus Genetics Q1 FY26 net loss widens to $65.5 million; revenue falls to $2.2 million

Opus Genetics Inc - Q1 Net Loss $0.75 per Share

THOMSON REUTERS

Press Release: Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Inc expected to post a loss of 14 cents a share - Earnings Preview

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Enovis (ENOV) and Revelation Biosciences (REVB)

Opus Genetics says OPGx-LCA5 trial restores cone-mediated vision in pediatric LCA5 patients

Opus Genetics completes cohort 1 enrollment in Phase 1/2 OPGx-BEST1 gene therapy study

Opus Genetics Inc - Three-Month Topline Results From Cohort 1 Expected in September 2026

THOMSON REUTERS

Opus Genetics says FDA accepts OPGx-LCA5 into Rare Disease Evidence Principles program

Opus Genetics Announces FDA Acceptance of Opgx-Lca5 Into Rare Disease Evidence Principles (Rdep) Program

THOMSON REUTERS

B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating

MT Newswires Live

Opus Genetics price target raised to $10 from $9 at B. Riley

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IRD/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":3.7,"timestamp":1788274674453,"preClose":3.62,"halted":0,"volume":209666,"delay":0,"changeRate":0.022099447513812175,"floatShares":65209799,"shares":83195823,"eps":-1.292468,"marketStatus":"Trading","change":0.08,"latestTime":"09-01 10:57:59 EDT","open":3.62,"high":3.75,"low":3.61,"amount":772624.346817,"amplitude":0.038674,"askPrice":3.71,"askSize":132,"bidPrice":3.7,"bidSize":33,"shortable":3,"etf":0,"ttmEps":-1.292468,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":3.62,"preHourTrading":{"tag":"盘前","latestPrice":3.6,"preClose":3.62,"latestTime":"09:03 EDT","volume":21264,"amount":77493.08415360001,"timestamp":1788267790759,"change":-0.02,"changeRate":-0.005525,"amplitude":0.135359},"postHourTrading":{"tag":"盘后","latestPrice":3.695,"preClose":3.62,"latestTime":"19:48 EDT","volume":12774,"amount":47073.3713,"timestamp":1788220125747,"change":0.075,"changeRate":0.020718,"amplitude":0.035912},"volumeRatio":1.064349,"impliedVol":0.6219,"impliedVolPercentile":0.0873},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":65209799,"roa":"-48.06%","roe":"-4796.52%","lyrEps":-0.8,"volumeRatio":1.064349,"shares":83195823,"dividePrice":0,"high":3.75,"amplitude":0.038674,"preClose":3.62,"low":3.61,"week52Low":1.22,"pbRate":"-23.70","psRate":"31.23","week52High":5.81,"institutionHeld":0,"latestPrice":3.7,"committee":-0.6,"eps":-1.292468,"divideRate":0,"volume":209666,"delay":0,"ttmEps":-1.292468,"open":3.62,"prevYearClose":2.01,"prevWeekClose":3.69,"prevMonthClose":3.62,"prevQuarterClose":4.11,"fiveDayClose":4.11,"twentyDayClose":3.71,"sixtyDayClose":4.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"IRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2026-05-12","symbol":"IRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2026-03-10","symbol":"IRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.11,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2632,"buy":0.7368,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7368,"analysts":19,"updateTime":1785556800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-08-31","current":-2.86274,"percent":0.244541,"low":-8.249622,"twenty":-2.987922,"median":-2.001473,"eighty":-1.130382,"high":-0.560128,"avg":-2.382162,"sd":1.791947,"marketCap":306992586},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-13","current":-3.427836,"twenty":-2.136977,"median":-1.323479,"eighty":-1.031375,"marketCap":233788665},{"date":"2026-02-20","current":-3.609844,"twenty":-2.149226,"median":-1.323479,"eighty":-1.038117,"marketCap":246202222},{"date":"2026-02-27","current":-3.630068,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"marketCap":247581506},{"date":"2026-03-06","current":-4.823238,"twenty":-2.163754,"median":-1.335088,"eighty":-1.055298,"marketCap":328959272},{"date":"2026-03-13","current":-6.821589,"twenty":-2.163832,"median":-1.335088,"eighty":-1.05838,"marketCap":338289413},{"date":"2026-03-20","current":-6.571003,"twenty":-2.174573,"median":-1.340893,"eighty":-1.062543,"marketCap":325862626},{"date":"2026-03-27","current":-6.48492,"twenty":-2.196211,"median":-1.358307,"eighty":-1.072721,"marketCap":321593683},{"date":"2026-04-02","current":-6.728822,"twenty":-2.279157,"median":-1.369917,"eighty":-1.078827,"marketCap":333689021},{"date":"2026-04-10","current":-7.890943,"twenty":-2.31549,"median":-1.383164,"eighty":-1.078974,"marketCap":391319747},{"date":"2026-04-17","current":-8.249622,"twenty":-2.347317,"median":-1.393136,"eighty":-1.079587,"marketCap":409107008},{"date":"2026-04-24","current":-7.474875,"twenty":-2.424764,"median":-1.39894,"eighty":-1.079843,"marketCap":370686524},{"date":"2026-05-01","current":-7.357517,"twenty":-2.49456,"median":-1.404745,"eighty":-1.081468,"marketCap":364866631},{"date":"2026-05-08","current":-7.717474,"twenty":-2.527902,"median":-1.450845,"eighty":-1.086096,"marketCap":382717249},{"date":"2026-05-15","current":-3.318654,"twenty":-2.605325,"median":-1.471353,"eighty":-1.089005,"marketCap":354870285},{"date":"2026-05-22","current":-2.864592,"twenty":-2.625631,"median":-1.50381,"eighty":-1.089833,"marketCap":306316604},{"date":"2026-05-29","current":-2.804496,"twenty":-2.764432,"median":-1.520037,"eighty":-1.093147,"marketCap":299890382},{"date":"2026-06-05","current":-3.098301,"twenty":-2.804496,"median":-1.567278,"eighty":-1.099183,"marketCap":331307470},{"date":"2026-06-12","current":-2.976252,"twenty":-2.841362,"median":-1.641006,"eighty":-1.10936,"marketCap":318256557},{"date":"2026-06-18","current":-3.09043,"twenty":-2.862186,"median":-1.648544,"eighty":-1.10936,"marketCap":330465888},{"date":"2026-06-26","current":-2.831626,"twenty":-2.921273,"median":-1.671763,"eighty":-1.117502,"marketCap":302791405},{"date":"2026-07-02","current":-3.181773,"twenty":-2.964753,"median":-1.703207,"eighty":-1.119538,"marketCap":340233353},{"date":"2026-07-10","current":-3.103979,"twenty":-3.005472,"median":-1.779688,"eighty":-1.123486,"marketCap":331914656},{"date":"2026-07-17","current":-2.5326,"twenty":-2.998741,"median":-1.85001,"eighty":-1.127372,"marketCap":270815938},{"date":"2026-07-24","current":-2.254631,"twenty":-2.977774,"median":-1.874663,"eighty":-1.129113,"marketCap":241092238},{"date":"2026-07-31","current":-2.964995,"twenty":-2.973207,"median":-1.900983,"eighty":-1.129716,"marketCap":317052806},{"date":"2026-08-07","current":-2.854241,"twenty":-2.967182,"median":-1.931317,"eighty":-1.129716,"marketCap":307144906},{"date":"2026-08-14","current":-2.87602,"twenty":-2.967182,"median":-1.947379,"eighty":-1.129716,"marketCap":309488461},{"date":"2026-08-21","current":-3.185269,"twenty":-2.973207,"median":-1.951541,"eighty":-1.129716,"marketCap":342766790},{"date":"2026-08-28","current":-2.976526,"twenty":-2.991855,"median":-1.986619,"eighty":-1.13016,"marketCap":320303918},{"date":"2026-08-31","current":-2.852826,"twenty":-2.987922,"median":-2.001473,"eighty":-1.130382,"marketCap":306992586}],"updateTime":1788274679744},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635769348","title":"Opus Genetics (IRD) Q1 Loss Of US$65.5 Million Intensifies Bearish Community Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2635769348","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635769348?lang=en_us&edition=fundamental","pubTime":"2026-05-14 10:27","pubTimestamp":1778725633,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) opened Q1 2026 with revenue of US$2.2 million and a basic EPS loss of US$0.75, putting a clear focus on how much cash the business is burning to support its growth plans. The company has reported quarterly revenue between US$2.9 million and US$4.4 million over the past five periods, while basic EPS losses have ranged from US$0.12 to US$1.16, giving investors a broad view of how the income statement changes as spending shifts. With profitability still some way off and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics/news/opus-genetics-ird-q1-loss-of-us655-million-intensifies-beari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics/news/opus-genetics-ird-q1-loss-of-us655-million-intensifies-beari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IRD.AU","IRD","BK7129","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635273373","title":"Opus Genetics Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2635273373","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635273373?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:31","pubTimestamp":1778682660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 10:31 ET (14:31 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780414","title":"Opus Genetics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780414","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780414?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:31","pubTimestamp":1778679105,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc reports results for the quarter ended March 31 - Earnings SummaryOpus Genetics Inc IRD.OQ reported a quarterly adjusted loss of 75 cents per share for the quarter ended March 31, low","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q1TC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635786540","title":"Opus Genetics to present at RBC Capital Markets Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2635786540","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635786540?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:01","pubTimestamp":1778670102,"startTime":"0","endTime":"0","summary":"Opus Genetics scheduled to present at RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026 at 11:00 a.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2FzJrm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200016","title":"Opus Genetics price target lowered to $11 from $12 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635200016?lang=en_us&edition=fundamental","pubTime":"2026-05-13 17:57","pubTimestamp":1778666238,"startTime":"0","endTime":"0","summary":"Citizens lowered the firm’s price target on Opus Genetics (IRD) to $11 from $12 and keeps an Outperform rating on the shares. Recent ARVO data cont...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-lowered-to-11-from-12-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-lowered-to-11-from-12-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635205425","title":"Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH) and Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635205425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635205425?lang=en_us&edition=fundamental","pubTime":"2026-05-13 15:20","pubTimestamp":1778656807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Option Care Health (OPCH) and Opus Genetics (IRD) wi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-option-care-health-opch-and-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-option-care-health-opch-and-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0012050646.USD","LU0106261612.USD","BK4137","XBI","XLV","BK4588","LABU","LU2065731478.USD","HCSG","BK4196","LU0029874061.USD","OPCH","BK4581","LU0128526141.USD","BK4139","BK4007","IRD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216446","title":"Opus Genetics reports Q1 EPS (75c), consensus (14c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216446","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216446?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:00","pubTimestamp":1778587232,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $2.16M, consensus $2.93M. “With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics (IRD) i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-reports-q1-eps-75c-consensus-14c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-reports-q1-eps-75c-consensus-14c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213535","title":"Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213535","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634213535?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:07","pubTimestamp":1778584020,"startTime":"0","endTime":"0","summary":"Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.14) by 435.71 percent. This is a 212.5 percent decrease over losses of $(0.24) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52480062/opus-genetics-q1-eps-0-75-misses-0-14-estimate-sales-2-157m-miss-2-931m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218751","title":"Opus Genetics Q1 FY26 net loss widens to $65.5 million; revenue falls to $2.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218751","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218751?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:04","pubTimestamp":1778583848,"startTime":"0","endTime":"0","summary":"Opus Genetics posted a net loss of USD 65.5 million, or USD 0.75 a share, for first-quarter 2026, widening from a year earlier on a USD 51.4 million non-cash loss tied to warrant liabilities.Revenue fell 50.6% year over year to USD 2.2 million, while research and development costs rose to USD 10.6 million.Cash and cash equivalents totaled USD 60 million at March 31; a strategic financing with Oberland Capital included USD 35 million of senior secured notes plus a USD 5 million equity commitment, with runway projected into 2029.Enrollment finished for Cohort 1 of OPGx-BEST1, with three-month topline data expected in September 2026; dosing for OPGx-LCA5 Phase 3 is expected to start in fourth-quarter 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL2VWH6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IRD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4007","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634213728","title":"Opus Genetics Inc - Q1 Net Loss $0.75 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2634213728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634213728?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA9NG6ZB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218059","title":"Press Release: Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218059?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:00","pubTimestamp":1778583600,"startTime":"0","endTime":"0","summary":"Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET. LCA5 Accepted to FDA's Rare Disease Evidence Principles  Program and Enrolling Pivotal Trial. RDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 Months. Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals. \"With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics is entering a defining stretch where we believe our precision targeted approach can reshape what's possible for patients with inherited retinal diseases,\" said George Magrath, M.D., Chief Executive Officer of Opus Genetics. \"Our upcoming BEST1 Cohort 1 clinical data and June R&D Science Forum will provide key opportunities to showcase the depth and maturity of our science and pipeline. Backed by a strong balance sheet and disciplined capital strategy, we are well-positioned to advance our lead programs toward p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634284432","title":"Opus Genetics Inc  expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634284432","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634284432?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:11","pubTimestamp":1778505065,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc  expected to post a loss of14cents a share - Earnings Preview Opus Genetics Inc IRD.OQ IRD.O is expected to  show a fall in quarterly revenue when it reports  results on May 13 (esti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O1ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634466502","title":"Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Enovis (ENOV) and Revelation Biosciences (REVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634466502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634466502?lang=en_us&edition=fundamental","pubTime":"2026-05-09 01:31","pubTimestamp":1778261477,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD), Enovis (ENOV) and Revelation Bi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-enovis-enov-and-revelation-biosciences-revb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-opus-genetics-ird-enovis-enov-and-revelation-biosciences-revb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","XLV","LU0128526141.USD","HCSG","IRD","XBI","BK4007","BK4588","LABU","REVB","BK4082","BK4139","LU0029874061.USD","IE00B19Z6F94.USD","LU2065732104.USD","IE0034390439.USD","ENOV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633089501","title":"Opus Genetics says OPGx-LCA5 trial restores cone-mediated vision in pediatric LCA5 patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2633089501","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633089501?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:45","pubTimestamp":1778190313,"startTime":"0","endTime":"0","summary":"Opus Genetics released new clinical results already presented at ARVO 2026 from ongoing Phase 1/2/3 study of OPGx-LCA5 in pediatric Leber congenital amaurosis type 5, showing patients regained meaningful daytime visual function following a single treatment.Separate early clinical findings already presented at ARVO from Phase 1b/2a OPGx-BEST1 study in an adult with BEST1-related disease indicated improved vision with signs of better retinal structure, supporting plans to broaden development in a larger inherited retinal disease population.Enrollment completed in Cohort 1 of Phase 1/2 OPGx-BEST1 study, with 3-month topline data scheduled for September 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9LSPbz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145232","title":"Opus Genetics completes cohort 1 enrollment in Phase 1/2 OPGx-BEST1 gene therapy study","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145232","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145232?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:09","pubTimestamp":1778152192,"startTime":"0","endTime":"0","summary":"Opus Genetics completed enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 gene therapy study in adults with Best disease, setting up a near-term readout for program momentum.Cohort 1 enrolled 5 participants across dominant and recessive forms; 4 have been treated, with final dosing scheduled this month.Baseline demographics were presented at ARVO, with 3-month results from first treated participant indicating the therapy was well tolerated with early signs of biological activity.Three-month topline results for full Cohort 1 will be released in September 2026, with a broader data presentation planned at an ophthalmology conference later in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original conten","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL6d0PN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633526145","title":"Opus Genetics Inc - Three-Month Topline Results From Cohort 1 Expected in September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633526145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633526145?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:06","pubTimestamp":1778152009,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nFWN41K0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633696919","title":"Opus Genetics says FDA accepts OPGx-LCA5 into Rare Disease Evidence Principles program","url":"https://stock-news.laohu8.com/highlight/detail?id=2633696919","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633696919?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:40","pubTimestamp":1777927203,"startTime":"0","endTime":"0","summary":"Opus Genetics investigational LCA5 gene therapy OPGx-LCA5 accepted into FDA Rare Disease Evidence Principles program.RDEP entry sets up early FDA engagement on regulatory strategy, including pivotal Phase 3 trial design for ultra-rare Leber congenital amaurosis type 5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLMZFy0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633966290","title":"Opus Genetics Announces FDA Acceptance of Opgx-Lca5 Into Rare Disease Evidence Principles (Rdep) Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2633966290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633966290?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:30","pubTimestamp":1777926601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUABCDNLG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632652517","title":"B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2632652517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632652517?lang=en_us&edition=fundamental","pubTime":"2026-04-30 23:02","pubTimestamp":1777561327,"startTime":"0","endTime":"0","summary":"Price: 5.18, Change: +0.51, Percent Change: +10.92","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631655591","title":"Opus Genetics price target raised to $10 from $9 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2631655591","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631655591?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:56","pubTimestamp":1777557368,"startTime":"0","endTime":"0","summary":"B. Riley raised the firm’s price target on Opus Genetics (IRD) to $10 from $9 and keeps a Buy rating on the shares. Published first on TheFly – the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-raised-to-10-from-9-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-price-target-raised-to-10-from-9-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":4,"totalSize":119,"code":"91000000","status":"200"}]}}